[DISCUSSION DRAFT]

115TH CONGRESS  
2D SESSION  
H. R. ______

To amend title XIX of the Social Security Act to require States to operate drug management programs for at-risk beneficiaries, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

M . ______ introduced the following bill; which was referred to the Committee on _______________________

A BILL

To amend title XIX of the Social Security Act to require States to operate drug management programs for at-risk beneficiaries, and for other purposes.

1 Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the “Medicaid Pharma-
5 ceutical Home Act of 2018”.

SEC. 2. DRUG MANAGEMENT PROGRAM FOR AT-RISK BENEFICIARIES.

(a) In General.—Title XIX of the Social Security Act is amended by inserting after section 1927 (42 U.S.C. 1396r–8) the following new section:

“SEC. 1927A. DRUG MANAGEMENT PROGRAM FOR AT-RISK BENEFICIARIES.

“(a) In General.—Beginning January 1, 2020, a State shall operate a qualified drug management program for at-risk beneficiaries identified by the State under the program.

“(b) Qualified Drug Management Program.—For purposes of this section, the term ‘qualified drug management program’ means, with respect to a State, a program carried out by the State (including through a contract with a pharmacy benefit manager) that provides at least for the following:

“(1) Identification of at-risk individuals.—Under the program, the State identifies, in accordance with subsection (c), individuals enrolled under the State plan (or waiver of the State plan) who are at-risk beneficiaries.

“(2) Elements of Program.—Under the program, the State, with respect to each individual identified under paragraph (1) and enrolled under the program under paragraph (5)—
“(A) selects at least one, but not more than three, health care providers and at least one, but not more than three, pharmacies for each such individual for purposes of subparagraph (B), in accordance with a selection process that takes into account reasonable factors such as the individual’s medical history with respect to receipt of items and services from health care providers and pharmacies, geographic proximity of the individual to health care providers and pharmacies, and access of the individual to health care; and

“(B) requires that any controlled substance furnished to such individual during the period for which such individual is enrolled under the program be prescribed by a health care provider selected under subparagraph (A) for such individual and dispensed by a pharmacy selected under subparagraph (A) for such individual in order for such controlled substance to be covered under the State plan (or waiver).

For purposes of subparagraph (A), in the case of a pharmacy that has multiple locations that share real-time electronic prescription data, all such loca-
tions of the pharmacy shall collectively be treated as
one pharmacy.

“(3) Notification to Identified Individuals.—Under the program, the State provides each
individual who is identified under paragraph (1),
before enrolling such individual under the pro-
gram—

“(A) notice that the State has identified
the individual as potentially being an at-risk
beneficiary for abuse or misuse of a controlled
substance;

“(B) information describing all State and
Federal public health resources that are de-
dsigned to address such abuse or misuse to
which the individual has access, including men-
tal health services and other counseling serv-
ices;

“(C) notice of, and information about, the
right of the individual to appeal such identifica-
tion under paragraph (4); and

“(D) an explanation of the meaning and
consequences of the identification of the indi-
vidual as potentially being an at-risk beneficiary
for abuse or misuse of a controlled substance,
including an explanation of the program.
“(4) APPEALS PROCESS.—Under the program, the State provides for an appeals process under which, with respect to an individual identified under paragraph (1)—

“(A) such individual may appeal—

“(i) such identification; and

“(ii) the selection of a health care provider or pharmacy under paragraph (2)(A); and

“(B) such individual is provided a period of not less than 30 days following the date of receipt of the notice described in paragraph (3) to submit such appeal.

“(5) ENROLLMENT.—Under the program, the State initially enrolls individuals who are identified under paragraph (1) in the program for a 12-month period—

“(A) in the case of such an individual who does not submit an appeal under paragraph (4) within the period applied by the State pursuant to subparagraph (B) of such paragraph, beginning on the day after the last day of such period; and

“(B) in the case of such an individual who does submit an appeal under paragraph (4)
within the period applied by the State pursuant to subparagraph (B) of such paragraph but such appeal is denied, beginning not later than 30 days after the date of such denial.

“(6) Notification of Health Care Providers and Pharmacies.—Under the program, the State provides to each health care provider and pharmacy selected for an individual under paragraph (2)—

“(A) notification that the individual is an at-risk beneficiary enrolled under the program and that the provider or pharmacy has been selected for the individual under paragraph (2); and

“(B) information on such program and the role of being so selected.

“(7) Continuation of Enrollment.—Under the program, the State, with respect to an individual enrolled under the program, provides for a process to—

“(A) not later than 30 days before the end of the 12-month period for which the individual is so enrolled pursuant to paragraph (5)—

“(i) assess, in accordance with publicly available evidence-based guidelines,
whether or not such individual should con-
tinue to be enrolled under the program;
and
“(ii) notify such individual of the re-
sults of the assessment under clause (i);
“(B) continue, subject to subparagraph
(C), enrollment of such individual if such as-
ssessment recommends such continuation; and
“(C) appeal the continuation of enrollment
in accordance with the appeals process de-
scribed in paragraph (4).
“(c) AT-RISK BENEFICIARY.—
“(1) IDENTIFICATION.—For purposes of this
section, a State shall identify an individual enrolled
under the State plan (or waiver of the State plan)
as an at-risk beneficiary if the individual is not an
exempted individual described in paragraph (2)
and—
“(A) is identified as such an at-risk bene-
iciary through the use of publicly available evi-
dence-based guidelines that indicate misuse or
abuse of a controlled substance; or
“(B) the State received notification from a
PDP sponsor or Medicare Advantage organiza-
tion that such individual was identified as being
an at-risk beneficiary for prescription drug
abuse for enrollment in a drug management
program established by the sponsor or organiza-
tion pursuant to section 1860D–4(e)(5) and
such identification has not been terminated
under subparagraph (F) of such section.

“(2) EXEMPTED INDIVIDUAL DESCRIBED.—For
purposes of paragraph (1), an exempted individual
described in this paragraph is an individual who—

“(A) receives hospice or palliative care;

“(B) is a resident of a long-term care facil-
ity, of a facility described in section 1905(d), or
of another facility for which frequently abused
drugs are dispensed for residents through a
contract with a single pharmacy; or

“(C) the State elects to treat as an ex-
empted individual for purposes of paragraph
(1).

“(d) APPLICATION OF PRIVACY RULES CLARIFICA-
TION.—The Secretary shall clarify privacy requirements,
including requirements under the regulations promulgated
pursuant to section 264(c) of the Health Insurance Port-
ability and Accountability Act of 1996 (42 U.S.C. 1320d–2
note), related to the sharing of data under subsection
(b)(6) in the same manner as the Secretary is required
under subparagraph (J) of section 1860D–4(c)(5) to clarify privacy requirements related to the sharing of data described in such subparagraph.

“(e) Reports.—

“(1) Annual reports.—

“(A) In general.—Not later than July 1 of each year (beginning with 2021), a State operating a qualified drug management program shall submit to the Administrator of the Centers for Medicare & Medicaid Services a report, with respect to the prior calendar year, that includes the following information:

“(i) The number of individuals enrolled under the State plan (or waiver of the State plan) who are enrolled under the program and the percentage of individuals enrolled under the State plan (or waiver) who are enrolled under such program.

“(ii) The number of prescriptions for controlled substances that were dispensed per month during each such year per individual enrolled under the program, including the dosage and pill count for each such prescription.
“(iii) The number of pharmacies filling prescriptions for controlled substances for individuals enrolled under such program.

“(iv) The number of health care providers writing prescriptions for controlled substances (other than prescriptions for a refill) for individuals enrolled under such program.

“(v) Any other data that the Secretary may require.

“(vi) Any report submitted by a managed care entity under subsection (e)(2) with respect to years.

For each such report for a year after 2021, the information described in this paragraph shall be provided in a manner that compares such information with respect to the prior calendar year to such information with respect to the second prior calendar year.

“(B) Public availability.—Not later than October 1 of each year (beg}
“(i) each report submitted by a State under paragraph (1) for such year; and

“(ii) all data collected from each such report, disaggregated by State, by States that provide medical assistance on a fee-for-service basis, and by States that provide medical assistance through a managed care entity.

“(2) MACPAC REPORTS AND REVIEW.—

“(A) INITIAL REPORT.—Not later than one year after the date of the enactment of this section, the Medicaid and CHIP Payment and Access Commission (in this section referred to as ‘MACPAC’), in consultation with the National Association of Medicaid Directors and any national association representing medicaid managed care organizations (as defined in section 1903(m)(1)(A)), shall publish a report on best practices for operating drug management programs, based on a review of a representative sample of States administering such a program. In establishing such best practices, the MACPAC shall consider how such programs have been implemented in rural areas, under fee-for-service as well as managed care arrange-
ments, and the extent to which such programs have resulted in increased efficiencies to such States or to the Federal Government under this title.

“(B) Subsequent review and report.—

“(i) Review.—The MACPAC, in consultation with the National Association of Medicaid Directors, shall review reports submitted under paragraph (1) for the first year for which reports are required under such paragraph and assess the data from such reports to determine trends and the effectiveness of qualified drug management programs operated under this section.

“(ii) Report.—Not later than two years after the date of the enactment of this section, the MACPAC, in consultation with the National Association of Medicaid Directors, shall publish a report, based on such review, that updates the best practices for operating drug management programs published under subparagraph (A) and makes recommendations to States on
how improvements can be made with respect to the operation of such programs.

“(3) REPORT ON PLAN FOR COORDINATED CARE.—Not later than January 1, 2021, each State operating a qualified drug management program shall submit to the Administrator of the Centers for Medicare & Medicaid Services a report on how such State plans to provide coordinated care for individuals enrolled under the State plan (or waiver of the State plan) and—

“(A) who are enrolled under the program;

or

“(B) who are enrolled with a managed care entity and enrolled under such a qualified drug management program operated by such entity.

“(f) APPLICABILITY TO MANAGED CARE ENTITIES.—

“(1) IN GENERAL.—With respect to any contract that a State enters into on or after January 1, 2020, with a managed care entity (as defined in section 1932(a)(1)(B)) pursuant to section 1903(m), the State shall, as a condition of the contract, require the managed care entity—

“(A) to operate a qualified drug management program (as defined in subsection (b)) for
at-risk beneficiaries who are enrolled with such
entity and identified by the managed care entity
by means of application of paragraph (2);

“(B) to submit to the State an annual re-
port on the matters described in clauses (i)
through (v) of subsection (e)(1)(A); and

“(C) submit to the State a list (and as
necessary update such list) of individuals en-
rolled with such entity under the qualified drug
management program operated by such entity
under subparagraph (A) for purposes of allow-
ing State plans for which medical assistance is
paid on a fee-for-service basis to have access to
such information.

“(2) APPLICATION.—For purposes of applying,
with respect to a managed care entity—

“(A) under paragraph (1)(A)—

“(i) the definition of the term ‘quali-
fied drug management program’ under
subsection (b); and

“(ii) the provisions of paragraphs (1)
and (2) of subsection (e); and

“(B) under paragraph (1)(B), the report
requirements described in clauses (i) through
(v) of subsection (e)(1)(A);
each reference in such subsection (b) and paragraph
of subsection (e) to ‘a State’ or ‘the State’ (other
than to ‘a State plan’ or ‘the State plan’) shall be
deemed a reference to the managed care entity, each
reference under such subsection, paragraphs, or
clauses to individuals enrolled under the State plan
(or waiver of the State plan) shall be deemed a ref-
ance to individuals enrolled with such entity, and
each reference under such subsection, paragraph, or
clauses to individuals enrolled under the qualified
drug management program operated by the State
shall be deemed a reference to individuals enrolled
under the qualified drug management program oper-
ated by the managed care entity.

“(g) CONTROLLED SUBSTANCE DEFINED.—For pur-
poses of this section, the term ‘controlled substance’
means a drug that is included in schedule II, III, or IV
of section 202(c) of the Controlled Substances Act.”.

(b) GUIDANCE ON AT-RISK POPULATION
TRANSITIONING TO MEDICARE.—

(1) IN GENERAL.—Not later than January 1,
2020, the Secretary of Health and Human Services,
after consultation with the Federal Coordinated
Health Care Office established under section 2602
of the Patient Protection and Affordable Care Act
(42 U.S.C. 1315b), shall issue guidance for State Medicaid programs, with respect to transitioning individuals, providing for—

(A) notification to be submitted by the State to the Centers for Medicare & Medicaid Services and such individuals of the status of such individuals as transitioning individuals;

(B) notification to such individuals about enrollment under a prescription drug plan under part D of such title or under a MA-PD plan under part C of such title;

(C) best practices for transitioning such individuals to such a plan; and

(D) best practices for coordination between the qualified drug management program (as described in section 1927A(b) of the Social Security Act, as added by subsection (a)) carried out by the State and a drug management program carried out under such a plan pursuant to section 1860D–4(e)(5) of the Social Security Act (42 U.S.C. 1395w–10(e)(5)).

(2) **TRANSITIONING INDIVIDUALS.**—For purposes of paragraph (1), a transitioning individual is an individual who, with respect to a month—
(A) is enrolled under the State plan (or waiver of the State plan) and under the qualified drug management program (as described in section 1927A(b) of the Social Security Act, as added by subsection (a)) carried out by the State; and

(B) is expected to become eligible for the Medicare program under title XVIII of such Act during the subsequent 12-month period.